Department of Diagnostic Radiology & Radiation Oncology, Medical school, Kochi University Nankoku, Kochi 783-8505, Japan.
Cancers (Basel). 2011 Sep 9;3(3):3496-505. doi: 10.3390/cancers3033496.
We introduced non-surgical therapy with a novel enzyme-targeting radiosensitization treatment, Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, Type II (KORTUC II) into early stages breast cancer treatment. The purpose of this study was to examine changes in tumor shadows and microcalcifications on mammography (MMG) following KORTUC II for elderly patients with breast cancer. We also sought to determine whether MMG was useful in evaluating the therapeutic effect of KORTUC II. In addition to MMG, positron emission tomography-computed tomography (PET-CT) was performed to detect both metastasis and local recurrence. In all 10 patients, tumor shadows on MMG completely disappeared in several months following the KORTUC II treatment. The concomitant microcalcifications also disappeared or markedly decreased in number. Disappearance of the tumors was also confirmed by the profile curve of tumor density on MMG following KORTUC II treatment; density fell and eventually approached that of the peripheral mammary tissue. These 10 patients have so far have also shown neither local recurrence nor distant metastasis on PET-CT with a mean follow-up period of approximately 27 months at the end of September, 2010. We conclude that breast-conservation treatment using KORTUC II, followed by aromatase inhibitor, is a promising therapeutic method for elderly patients with breast cancer, in terms of avoiding any surgical procedure. Moreover, MMG is considered to be useful for evaluating the efficacy of KORTUC II.
我们将一种新型的酶靶向增敏放射治疗——Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, Type II(KORTUC II)引入早期乳腺癌的治疗中。本研究的目的是探讨 KORTUC II 治疗老年乳腺癌患者后乳腺 X 线摄影(MMG)上肿瘤阴影和微钙化的变化,并确定 MMG 是否有助于评估 KORTUC II 的治疗效果。除了 MMG 之外,我们还进行了正电子发射断层扫描-计算机断层扫描(PET-CT),以检测转移和局部复发。在所有 10 例患者中,KORTUC II 治疗后数月内 MMG 上的肿瘤阴影完全消失。同时存在的微钙化也消失或明显减少。MMG 上的肿瘤密度曲线也证实了肿瘤的消失,密度下降,最终接近周围乳腺组织的密度。截至 2010 年 9 月底,这些患者的平均随访时间约为 27 个月,在 PET-CT 上均未发现局部复发或远处转移。我们的结论是,对于老年乳腺癌患者,KORTUC II 联合芳香酶抑制剂进行保乳治疗,避免了手术,是一种很有前途的治疗方法。此外,MMG 被认为有助于评估 KORTUC II 的疗效。